Advertisement
UK markets close in 8 hours 23 minutes

  • FTSE 100

    8,040.38
    0.00 (0.00%)
     

  • FTSE 250

    19,719.37
    0.00 (0.00%)
     

  • AIM

    754.69
    0.00 (0.00%)
     

  • GBP/EUR

    1.1657
    +0.0013 (+0.11%)
     

  • GBP/USD

    1.2493
    +0.0030 (+0.24%)
     

  • Bitcoin GBP

    51,456.94
    -1,963.93 (-3.68%)
     

  • CMC Crypto 200

    1,389.72
    +7.15 (+0.52%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    83.05
    +0.24 (+0.29%)
     

  • GOLD FUTURES

    2,334.40
    -4.00 (-0.17%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,272.73
    +71.46 (+0.42%)
     

  • DAX

    18,088.70
    -48.95 (-0.27%)
     

  • CAC 40

    8,091.86
    -13.92 (-0.17%)
     
Property:

How to sell your home

Top tips from property investors

Company News for Dec 5, 2019

Zacks Equity Research

  • HealthEquity Inc. HQY shares surge 3.4% after the company reported third-quarter fiscal 2020 adjusted earnings per share of $0.47, beating the Zacks Consensus Estimate of $0.22.

  • salesforce.com inc. CRM tumbled 3.2% after the company reduced its fiscal 2020 sales guidance to down 1% to up 1% from up 1% to up 3% provided earlier.

  • Shares of Campbell Soup Co. CPB increased 1.9% after posting first-quarter fiscal 2020 adjusted earnings per share of $0.78, surpassing the Zacks Consensus Estimate of $0.69.

  • Royal Bank of Canada RY dropped 1.5% after reporting fourth-quarter fiscal 2019 adjusted earnings per share of $1.68, outpacing the Zacks Consensus Estimate of $1.74.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Royal Bank Of Canada (RY) : Free Stock Analysis Report
 
salesforce.com, inc. (CRM) : Free Stock Analysis Report
 
Campbell Soup Company (CPB) : Free Stock Analysis Report
 
HealthEquity, Inc. (HQY) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research